Search Results - diabetes

14 Results

Sort By:

Lipid Nanoparticles as Oral Vehicles of Immunotherapy

Unmet NeedType 1 diabetes (T1D) affects 1.25 million Americans currently and by 2050, this number is expected to reach 5 million. Though a currently untreatable autoimmune disease, one of the more promising approaches has been a costimulatory blockade of malfunctioning immune cells via administration of CTLA4-Ig. However, its efficacy is impeded by...

Published: 3/14/2025 | Inventor(s): Giorgio Raimondi, Julia Patrone, Xiomara Calderon-Colon, Olivia Tiburzi

Keywords(s): Diabetes, Disease Indication, Drug Delivery Mechanism, Drug Delivery Vehicle, Immunotherapy, Metabolic Disorders, Nanoparticles, Oral Administration, Single, Therapeutic Matter, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations > Diabetes > Type 1 Diabetes, Clinical and Disease Specializations > Diabetes, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms

A Novel mAb20-based In-cell ZnT8 Assay

Unmet Need: Prevalence of Type 2 Diabetes (T2D) continues to rapidly increase worldwide, contributing significant economic and global health burdens. There is an urgent need for the development of novel therapeutic strategies to treat T2D.Technical Details: Johns Hopkins researchers have identified a novel target to treat T2D and report here the development...

Published: 3/14/2025 | Inventor(s): Dax Fu, Chengfeng Merriman

Keywords(s): Analytical Method, Diabetes, Discovery/Research Tools, Disease Indication, In Vitro Research Tool, Metabolic Disorders, Proteomics/Immunoassays, Research Reagent, Target-based Screening Tool, Type II Diabetes

Category(s): Clinical and Disease Specializations > Diabetes > Type 2 Diabetes, Technology Classifications > Research Tools > Assays, Technology Classifications > Therapeutic Modalities > Targets

Highly Specific Monoclonal Antibodies used as Allosteric Inhibitors and Specific Biosensors of Human ZnT8

Unmet NeedType 2 diabetes (T2D) is a growing worldwide public health issue affecting over 500 million people while creating a $1 trillion economic burden on global healthcare economies. Many current and new therapeutics demonstrate varying degrees of effectiveness, but no single agent or combination thereof has been able to provide patients with lasting...

Published: 3/14/2025 | Inventor(s): Dax Fu, Chengfeng Merriman

Keywords(s): Antibodies, Biologics, Diabetes, Discovery/Research Tools, Disease Indication, Metabolic Disorders, Monoclonal Antibodies, Research Reagent, Therapeutic Matter, Therapeutic Substance, Therapeutics, Translational Research Biomarker, Type II Diabetes

Category(s): Technology Classifications > Research Tools > Research Antibodies, Clinical and Disease Specializations > Diabetes > Type 2 Diabetes, Technology Classifications > Therapeutic Modalities > Therapeutic Antibodies

An ECL-based Autoantibody Assay for Early Diagnosis of T1D Using a Membrane-spanning ZnT8 Antigenic Domain

Unmet NeedApproximately 1.25 million people in the US have type 1 diabetes (T1D) and the rates of newly diagnosed cases in children are on the rise each year. T1D is caused by the development of an autoimmune reaction to pancreatic β cells. The first detectable sign of β cell autoimmunity is the appearance of diabetes-associated autoantibodies, which...

Published: 3/14/2025 | Inventor(s): Dax Fu, Chengfeng Merriman, Liping Yu, Yong Gu

Keywords(s): Assay, Biomarker, Clinical Diagnostics, Diabetes, Diagnostic Biomarker, Diagnostic Tool, Disease Indication, In Vitro Diagnostics (Old), Measurement Tool, Metabolic Disorders, Type II Diabetes

Category(s): Clinical and Disease Specializations > Diabetes > Type 1 Diabetes, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Diagnostics > In Vivo Diagnostics, Clinical and Disease Specializations > Diabetes > Type 2 Diabetes, Technology Classifications > Diagnostics > Diagnostic Biomarkers

Non-invasive Diagnostic Biomarker for Pancreatic Islet Populations

Unmet NeedAffecting more than 230 million people worldwide, diabetes is a chronic disease caused by a deficiency and/or resistance to insulin. Insulin production is controlled by the pancreas, specifically by the pancreatic islets, a region of the pancreas that contains the hormone-producing cells. The pancreatic islets are made up of at least 5 different...

Published: 3/13/2025 | Inventor(s): Richard Edden, Eric Porges, Damon Lamb, Martha Thompson

Keywords(s): Biomarker, Clinical Diagnostics, Diabetes, Diagnostic Biomarker, Disease Indication, Image Processing Software, Imaging and Sensing Systems, In Vitro Diagnostics, In Vivo Medical Imaging, Metabolic Disorders

Hepatic Kisspeptin Secretion Impairs Insulin Secretion from Pancreatic Bets Cell. Kisspeptin Receptor GPR54 Antagonist for Treatment of Prediabetes and Diabetes Mellitus in Humans.

Unmet NeedGlucagon and insulin work together to keep blood glucose levels balanced. Glucagon stimulates the liver to secrete glucose while insulin suppresses glucose release. If the body does not regulate glucose levels properly, Type 2 diabetes mellitus (T2DM) will develop. Type 2 diabetes mellitus is a world-wide epidemic, projected to affect 1/3...

Published: 3/13/2025 | Inventor(s): Woo-Jin Song, Prosenjit Mondal, Mehboob Hussain

Keywords(s): Biomarker, Diabetes, Disease Indication, Mechanism-of-action Biomarker, Metabolic Disorders, Therapeutic Matter, Therapeutics, Type 2 Diabetes, Type II Diabetes

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Metabolic Diseases, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Therapeutic Modalities > Targets, Clinical and Disease Specializations > Diabetes, Technology Classifications > Diagnostics, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Diabetes > Type 2 Diabetes

Methods and Kits for Identifying Autoreactive Lymphocytes in Type 1 Diabetes and Other Autoimmune Disease

Unmet NeedAutoreactive lymphocytes contribute to the pathogenesis of autoimmune diseases including, type 1 diabetes, multiple sclerosis, and systemic lupus erythematosus (SLE). One of the challenges in studying these populations of lymphocytes, also known as X- cells, is that there are no biomarkers to distinguish them from protective T cells and B...

Published: 3/13/2025 | Inventor(s): Abdel Rahim Hamad, Thomas Donner, Rizwan Ahmed, Zahra Omidian

Keywords(s): Biomarker, Clinical Diagnostics, Diabetes, Diagnostic Biomarker, Disease Indication, In Vitro Diagnostics, Metabolic Disorders

An Insulin-loaded Nanoparticle and the Method for Preparing Thereof

Unmet Need:Repeated injections of insulin is the standard of care for treating Type 1 diabetes, and essential for control and management of Type 2 diabetes. Drawbacks of this treatment include poor patient compliance, discomfort, and an impaired lifestyle, and hypoglycemia. Oral administration of insulin, if successful, could deliver insulin such that...

Published: 3/13/2025 | Inventor(s): Hai-Quan Mao, Jose Santos, Zhiyu He, Huahua Huang, Lixin Liu, Kam Leong, Yongming Chen

Keywords(s): Diabetes, Disease Indication, Drug Delivery Vehicle, Metabolic Disorders, Nanoparticles, Therapeutic Matter, Therapeutic Method, Therapeutics

Three-dimensional Vascular Network Assembly from Diabetic Patient-derived Induced Pluripotent Stem Cells

In diabetics, hyperglycemia results in deficient endothelial progenitors and cells, leading to cardiovascular complications. We aim to engineer three-dimensional (3D) vascular networks in synthetic hydrogels from type-1 diabetes (T1D) patient-derived human induced pluripotent stem cells (hiPSCs), thus serving as a transformative autologous vascular...

Published: 3/13/2025 | Inventor(s): Sharon Gerecht, Xin Yi Chan, Quinton Smith, Yu-I Shen

Keywords(s): Biologics, Cell Model, Diabetes, Discovery/Research Tools, Disease Indication, In Vitro Research Tool, Metabolic Disorders, Stem Cells, Therapeutic Matter, Therapeutic Substance, Therapeutic Substance Synthesis Method, Therapeutics, Translational Research Biomarker, Whole cell

CTD110.6 monoclonal antibody

C03770: CTD110.6 monoclonal antibody Technical Details: O-linked N-acetylglucosamine (O-GlcNAc) is a newly described but ubiquitous dynamic modification of key regulatory proteins in side virtually all multi-cellular eukaryotic cells. Recently, this sugar modification has been shown to be as abundant as protein phosphorylation, often competing with...

Published: 3/13/2025 | Inventor(s): Frank Comer, Gerald Hart

Keywords(s): Alzheimer's Disease, Antibodies, Biologics, Cancers, CNS and Neurological Disorders, Diabetes, Discovery/Research Tools, Disease Indication, Metabolic Disorders, Monoclonal Antibodies, Research Reagent, Therapeutic Matter, Therapeutic Substance, Therapeutics, Translational Research Biomarker

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Diabetes, Clinical and Disease Specializations > Metabolic Diseases, Clinical and Disease Specializations > Neurology, Clinical and Disease Specializations > Oncology, Technology Classifications > Research Tools > Antibodies, Technology Classifications > Therapeutic Modalities > Antibodies, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Research Tools, Technology Classifications > Therapeutic Modalities

1 2